18F-fluciclovine PET Discrimination of Radiation Injury to the Brain

Overview

About this study

The goal of this study is to further evaluate the ability of fluciclovine PET to discriminate between radiation necrosis and tumor progression in patients with previously irradiated intracranial metastatic disease. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Registration – Inclusion Criteria

  •  Age ≥ 18 years old.
  • Clinical evidence of intracranial metastatic disease which underwent radiation and who presents with MRI findings suspicious for recurrent disease and/or radionecrosis (namely the ‘index lesion’).

Registration - Exclusion Criteria:

  • Contraindication to contrast enhanced MRI.
  • Females of child-bearing potential who are pregnant or lactating or who are not using adequate contraception (surgical, hormonal or double barrier; i.e., condom and diaphragm).
  • Inability to lie still for 50 minutes during fluciclovine PET-MRI imaging. 
  • Inability or refusal to consent.
  • Allergy or anaphylaxis to any of the reagents used in this study.
  • Inability or unwillingness to return for required visits and follow-up exams.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Daniel Trifiletti, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions